DDInter1156 DDInter1676
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mercaptopurine {u} (Compound) resembles {v} (Compound) Adenine
Mercaptopurine {u} (Compound) treats {v} (Disease) Crohn's disease
Mercaptopurine {u} (Compound) binds {v} (Gene) AOX1
Mercaptopurine {u} (Compound) causes {v} (Side Effect) Candida infection
Mercaptopurine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Mercaptopurine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Mercaptopurine {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Mercaptopurine {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Mercaptopurine (Compound) resembles Adenine (Compound)
Mercaptopurine (Compound) treats Crohn's disease (Disease)
Mercaptopurine (Compound) binds AOX1 (Gene)
Mercaptopurine (Compound) causes Candida infection (Side Effect)
Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Mercaptopurine may lead to a major life threatening interaction when taken with Certolizumab pegol
Mercaptopurine may lead to a major life threatening interaction when taken with Natalizumab